{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:41:44Z","timestamp":1793994104574,"version":"4.8.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.clinthera.2022.02.004","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T07:43:00Z","timestamp":1646034180000},"page":"521-538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma"],"prefix":"10.1016","volume":"44","author":[{"given":"Julia Thornton","family":"Snider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"McMorrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6509-4229","authenticated-orcid":false,"given":"David","family":"Diakun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally W.","family":"Wade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.02.004_bib0001","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0002","unstructured":"SEER Cancer Stat Facts: Diffuse Large B-Cell Lymphoma. National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html."},{"key":"10.1016\/j.clinthera.2022.02.004_bib0003","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1634\/theoncologist.2014-0113","article-title":"Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis","volume":"19","author":"Hamlin","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0004","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1200\/JCO.2005.05.015","article-title":"State-of-the-art therapeutics: diffuse large B-cell lymphoma","volume":"23","author":"Coiffier","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0005","first-page":"393","article-title":"Improving outcomes for patients with diffuse large B-cell lymphoma","volume":"60","author":"Flowers","year":"2010","journal-title":"CA: a cancer journal for clinicians"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0006","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0007","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0008","unstructured":"B-cell Lymphomas (version 5.2019). 2019; https:\/\/www.nccn.org. Accessed October 1, 2019."},{"key":"10.1016\/j.clinthera.2022.02.004_bib0009","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.13463","article-title":"Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis","volume":"170","author":"Howlett","year":"2015","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0010","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0011","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.bbmt.2011.10.010","article-title":"High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry","volume":"18","author":"Mounier","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0012","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.2001.19.2.406","article-title":"Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry","volume":"19","author":"Vose","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0013","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood.V96.7.2399","article-title":"High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis","volume":"96","author":"Kewalramani","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0014","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.1998.16.1.48","article-title":"Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens\u2013a Southwest Oncology Group trial","volume":"16","author":"Stiff","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0015","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/10428194.2016.1228924","article-title":"Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy","volume":"58","author":"Danese","year":"2017","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0016","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1080\/10428194.2018.1459613","article-title":"Costs of relapsed diffuse large B-cell lymphoma among Medicare patients","volume":"59","author":"Huntington","year":"2018","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0017","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1080\/10428194.2019.1623886","article-title":"Temporal trends in treatment and survival of older adult diffuse large B-Cell lymphoma patients in the SEER-Medicare linked database","volume":"60","author":"Shaw","year":"2019","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0018","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2217\/fon-2020-0522","article-title":"Real-world practice patterns and outcomes in Veterans with relapsed\/refractory diffuse large B-cell lymphoma","volume":"17","author":"Chien","year":"2020","journal-title":"Future Oncology"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0019","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.2217\/fon-2018-0267","article-title":"Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA","volume":"14","author":"Morrison","year":"2018","journal-title":"Future Oncology"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0020","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1634\/theoncologist.2018-0490","article-title":"Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies","volume":"24","author":"Purdum","year":"2019","journal-title":"The Oncologist"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0021","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2217\/fon-2018-0788","article-title":"Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA","volume":"15","author":"Morrison","year":"2019","journal-title":"Future Oncology"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0022","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1080\/10428194.2019.1581932","article-title":"Complications and hospital costs during hematopoietic stem cell transplantation for non-Hodgkin lymphoma in the United States","volume":"60","author":"Cho","year":"2019","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0023","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/cncr.23281","article-title":"In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies","volume":"112","author":"Jones","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0024","unstructured":"SEER-Medicare: Calculation of Comorbidity Weights https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/calculation.html. Accessed March 6, 2017."},{"key":"10.1016\/j.clinthera.2022.02.004_bib0025","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol."},{"key":"10.1016\/j.clinthera.2022.02.004_bib0026","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0027","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study","volume":"35","author":"van Imhoff","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0028","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0029","unstructured":"Consumer Price Index details report tables https:\/\/www.bls.gov\/cpi\/home.htm. Accessed October 1, 2020."},{"key":"10.1016\/j.clinthera.2022.02.004_bib0030","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1080\/10428194.2020.1734592","article-title":"The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy","volume":"61","author":"Tkacz","year":"2020","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0031","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood.V112.11.2373.2373","article-title":"Payer Costs of Autologous Stem Cell Transplant: Results from a U.S. Claims Data Analysis","volume":"112","author":"Pelletier","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0032","first-page":"366","article-title":"The Cost of Hematopoietic Stem-Cell Transplantation in the United States","volume":"10","author":"Broder","year":"2017","journal-title":"American health & drug benefits"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0033","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/14737167.2019.1680288","article-title":"Cost burden of diffuse large B-cell lymphoma","volume":"19","author":"Harkins","year":"2019","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"10.1016\/j.clinthera.2022.02.004_bib0034","first-page":"1","article-title":"2017 US organ and tissue transplant cost estimates and discussion","author":"Bentley","year":"2017","journal-title":"Milliman Research Report"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0035","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/10428194.2017.1375100","article-title":"Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma","volume":"59","author":"Maziarz","year":"2018","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.clinthera.2022.02.004_bib0036","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1080\/10428194.2017.1390230","article-title":"Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma","volume":"59","author":"Chen","year":"2018","journal-title":"Leuk Lymphoma"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822000510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822000510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:56:32Z","timestamp":1758963392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822000510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0149291822000510"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.02.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}